P2278 Unexpected findings in anticoagulation management in patients with valvular heart disease after valve surgery

2003 ◽  
Vol 24 (5) ◽  
pp. 437
Author(s):  
C GOHLKEBARWOLF
Author(s):  
Benjamin Wessler ◽  
Christine Lundquist ◽  
Gowri Raman ◽  
Jennifer Lutz ◽  
Jessica Paulus ◽  
...  

Background: Interventions for patients with valvular heart disease (VHD) now include both surgical and percutaneous procedures. As a result, treatments are being offered to increasingly complex patients with a significant burden of non-cardiac comorbid conditions. There is a major gap in our understanding of how various comorbidities relate to prognosis following interventions for VHD. Here we describe how comorbidities are handled in clinical predictive models for patients undergoing interventions for VHD. Methods: We queried the Tufts Predictive Analytics and Comparative Effectiveness (PACE) Clinical Prediction Model (CPM) Registry to identify de novo CPMs for patients undergoing VHD interventions. We systematically extracted information on the non-cardiac comorbidities contained in the CPMs and also measures of model performance. Results: From January 1990- May 2012 there were 12 CPMs predicting measures of morbidity or mortality for patients undergoing interventions for VHD. There were 2 CPMs predicting outcomes for isolated aortic valve replacement, 3 CPMs predicting outcomes for isolated mitral valve surgery, and 7 models predicting outcomes for a combination of valve surgery subtypes. Ten out of twelve (83%) of the CPMs for patients undergoing interventions for VHD predicted mortality. The median number of non-cardiac comorbidities included in the CPMs was 4 (range 0-7). All of the CPMs predicting mortality included at least 1 comorbid condition. The top 3 most common comorbidities included in these CPMs were, renal dysfunction (10/12, 83%), prior CVA (7/12, 58%) and measures of BMI/BSA (7/12, 58%). Diabetes was present in only 25% (3/12) of the models and chronic lung disease in only 17% (2/12). Conclusions: Non-cardiac comorbidities are frequently found in CPMs predicting morbidity and mortality following interventions for VHD. There is significant variation in the number and type of specific comorbid conditions included in these CPMs. More work is needed to understand the directionality, magnitude, and consistency of effect of these non-cardiac comorbid conditions for patients undergoing interventions for VHD.


Medicina ◽  
2019 ◽  
Vol 55 (8) ◽  
pp. 437
Author(s):  
Giuseppe Palmiero ◽  
Enrico Melillo ◽  
Antonino Salvatore Rubino

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation.


2003 ◽  
Vol 81 (2) ◽  
pp. 151-156 ◽  
Author(s):  
M. Malhotra ◽  
J.B. Sharma ◽  
P. Arora ◽  
S. Batra ◽  
S. Sharma ◽  
...  

2013 ◽  
Vol 7 (1) ◽  
pp. 104-109 ◽  
Author(s):  
Konstantinos Dean Boudoulas ◽  
Yazhini Ravi ◽  
Daniel Garcia ◽  
Uksha Saini ◽  
Gbemiga G. Sofowora ◽  
...  

Aim: While the incidence of rheumatic heart disease has declined dramatically over the last half-century, the number of valve surgeries has not changed. This study was undertaken to define the most common type of valvular heart disease requiring surgery today, and determine in-hospital surgical mortality and length-of-stay (LOS) for isolated aortic or mitral valve surgery in a United States tertiary-care hospital. Methods: Patients with valve surgery between January 2002 to June 2008 at The Ohio State University Medical Center were studied. Patients only with isolated aortic or mitral valve surgery were analyzed. Results: From 915 patients undergoing at least aortic or mitral valve surgery, the majority had concomitant cardiac proce-dures mostly coronary artery bypass grafting (CABG); only 340 patients had isolated aortic (n=204) or mitral (n=136) valve surgery. In-hospital surgical mortality for mitral regurgitation (n=119), aortic stenosis (n=151), aortic insufficiency (n=53) and mitral stenosis (n=17) was 2.5% (replacement 3.4%; repair 1.6%), 3.9%, 5.6% and 5.8%, respectively (p=NS). Median LOS for aortic insufficiency, aortic stenosis, mitral regurgitation, and mitral stenosis was 7, 8, 9 (replacement 11.5; repair 7) and 11 days, respectively (p<0.05 for group). In-hospital surgical mortality for single valve surgery plus CABG was 10.2% (p<0.005 compared to single valve surgery). Conclusions: Aortic stenosis and mitral regurgitation are the most common valvular lesions requiring surgery today. Surgery for isolated aortic or mitral valve disease has low in-hospital mortality with modest LOS. Concomitant CABG with valve surgery increases mortality substantially. Hospital analysis is needed to monitor quality and stimulate improvement among Institutions.


Sign in / Sign up

Export Citation Format

Share Document